Also, different approaches with drugs that individually activate the receptors for different catabolic gut hormones have not provided the expected beneficial results, and the GLP1 analog liraglutide has been the only one to be approved by the US Food and Drug Administration (FDA) and the European Medicines Evaluation Agency (EMEA) for the treatment of obesity. The gene discussed is GLP1R; the disease is obesity disorder.